Item 5. Other Information
Item 5. Other Information.
[None.]
Item 6. Exhibits.
The exhibits filed
or furnished as part of this Quarterly Report on Form 10-Q are set forth below.
Incorporate
by
Exhibit
Number
Description
Form
File No
Date of
Filing
Exhibit
No.
Filed
Herewith
31.1
Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.
X
31.2
Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.
X
32.1(1)
Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
X
32.2(2)
Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
X
101.INS
XBRL Instance Document
X
101.SCH
Inline XBRL Taxonomy Extension Schema Document
X
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document
X
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document
X
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase Document
X
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document
X
(1) The certifications on Exhibit 32 hereto are deemed not “filed” for purposes of Section
18 of the Exchange Act or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated
by reference into any filing under the Securities Act or the Exchange Act.
22
SIGNATURES
Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date: August 14, 2020
ANCHIANO THERAPEUTICS LTD.
By:
/s/ Ruth Alon
/s/ Neil Cohen
Ruth Alon
Neil Cohen
Director
Director
(Principal Executive Officer)
Following the resignation of the Company’s Chief Executive
Officer, Dr. Frank Haluska, on July 2, 2020, the Board of Directors assumed primary responsibility for the management of the Company.
The directors whose signatures appear above are signing this document on behalf of the full Board of Directors.
23
SIGNATURES
Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date: August 14, 2020
ANCHIANO THERAPEUTICS LTD.
By:
/s/ Andrew Fine
Andrew Fine
Interim Chief Financial Officer
(Principal Accounting Officer and Principal Financial Officer and duly Authorized Signatory)
24
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.